AU2021292484A1 - ALK2 inhibitors for the treatment of anemia - Google Patents

ALK2 inhibitors for the treatment of anemia Download PDF

Info

Publication number
AU2021292484A1
AU2021292484A1 AU2021292484A AU2021292484A AU2021292484A1 AU 2021292484 A1 AU2021292484 A1 AU 2021292484A1 AU 2021292484 A AU2021292484 A AU 2021292484A AU 2021292484 A AU2021292484 A AU 2021292484A AU 2021292484 A1 AU2021292484 A1 AU 2021292484A1
Authority
AU
Australia
Prior art keywords
compound
formula
mds
administered
anemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2021292484A
Other languages
English (en)
Inventor
Ekaterine ASATIANI
Yaoyu CHEN
Francis SÉGUY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2021292484A1 publication Critical patent/AU2021292484A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021292484A 2020-06-16 2021-06-15 ALK2 inhibitors for the treatment of anemia Withdrawn AU2021292484A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US63/039,742 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US63/056,761 2020-07-27
US202163152516P 2021-02-23 2021-02-23
US63/152,516 2021-02-23
PCT/US2021/037377 WO2021257532A1 (en) 2020-06-16 2021-06-15 Alk2 inhibitors for the treatment of anemia

Publications (1)

Publication Number Publication Date
AU2021292484A1 true AU2021292484A1 (en) 2023-01-19

Family

ID=76845323

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021292484A Withdrawn AU2021292484A1 (en) 2020-06-16 2021-06-15 ALK2 inhibitors for the treatment of anemia

Country Status (13)

Country Link
US (2) US11723899B2 (cg-RX-API-DMAC7.html)
EP (1) EP4164641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530316A (cg-RX-API-DMAC7.html)
KR (1) KR20230025444A (cg-RX-API-DMAC7.html)
CN (1) CN115968289B (cg-RX-API-DMAC7.html)
AU (1) AU2021292484A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187767A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022003511A1 (cg-RX-API-DMAC7.html)
IL (1) IL298767A (cg-RX-API-DMAC7.html)
MX (1) MX2022015900A (cg-RX-API-DMAC7.html)
PH (1) PH12022553501A1 (cg-RX-API-DMAC7.html)
TW (1) TW202214239A (cg-RX-API-DMAC7.html)
WO (1) WO2021257532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
IL298767A (en) * 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
JP4198183B2 (ja) 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
EP2069313A2 (en) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
EP3344613B1 (en) 2015-08-31 2020-03-04 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20220372136A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia

Also Published As

Publication number Publication date
CN115968289A (zh) 2023-04-14
US12383541B2 (en) 2025-08-12
IL298767A (en) 2023-02-01
EP4164641A1 (en) 2023-04-19
PH12022553501A1 (en) 2024-04-22
CL2022003511A1 (es) 2023-06-02
US20230338352A1 (en) 2023-10-26
TW202214239A (zh) 2022-04-16
WO2021257532A1 (en) 2021-12-23
CL2023001952A1 (es) 2023-12-15
MX2022015900A (es) 2023-01-24
CA3187767A1 (en) 2021-12-23
KR20230025444A (ko) 2023-02-21
CN115968289B (zh) 2025-09-30
US11723899B2 (en) 2023-08-15
JP2023530316A (ja) 2023-07-14
US20210393605A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US12383541B2 (en) ALK2 inhibitors for the treatment of anemia
US11738026B2 (en) Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
US11793802B2 (en) Treatment of acute myeloid leukemia (AML) with venetoclax failure
KR20230028484A (ko) 암의 치료를 위한 병용 요법
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2018158225A1 (en) Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
AU2022234219B2 (en) Methods of treating cancer using a combination of serd dosing regimens
EA049111B1 (ru) Ингибиторы alk2 для лечения анемии
TW202408485A (zh) 用於減少癌症治療中不良副作用之組合物及方法
AU2005251588B2 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
CN118678960A (zh) 用于治疗癌症的方法和组合物
JP2023539788A (ja) 口内乾燥症の治療剤
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
EA049147B1 (ru) Комбинированный лекарственный препарат, содержащий ингибитор alk2 и ингибитор jak2
CA3227813A1 (en) Pharmaceutical composition for treating solid tumors
JP2026514917A (ja) 肝臓のみに転移したぶどう膜黒色腫を処置する方法
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用

Legal Events

Date Code Title Description
MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal